The transgenic rodent (TGR) assay has been widely used to study in vivo gene mutations by chemicals or radiation; however, an optimal protocol has not yet been established to assess unknown genotoxic potential. The International Workshop on Genotoxicity Testing (IWGT) strongly recommends a repeated-dose regimen for the TGR assay protocol for regulatory safety assessment as follows: a treatment period of 28 days and a sampling time of 3 days following theˆnal treatment. In this study, TGR assays using F344 gpt delta transgenic rats were conducted at three laboratories to evaluate the validity of the IWGT protocol, as part of a collaborative study of the transgenic rat mutation assay. Male F344 gpt delta transgenic rats were orally treated with 2,4-diaminotoluene (2,4-DAT; hepatic carcinogen in rodents; 10 and 30 mg/kg/day) or 2,6-diaminotoluene (2,6-DAT; non-carcinogen in rodents; 60 mg/ kg/day) once daily for 28 days. Rats were euthanized 3 days after the last dosing, and then mutant frequencies (MFs) of the gpt gene in the livers were studied. As a result, a signiˆcant increase in the MF was observed at 30 mg/kg in the 2,4-DAT-treated group, but not in the 2,6-DAT-treated group. These results were commonly observed among the three laboratories. In addition, the overall results from the three laboratories were in general agreement. These results indicate that 2,4-DAT induces gene mutation in the liver of gpt delta rats, but 2,6-DAT does not. These results also indicate that the F344 gpt delta transgenic rat mutation assay can distinguish diŠer-ences in the in vivo mutagenic potential between a hepatic carcinogen and a non-carcinogen. Results from one laboratory showed more variability than those from the other two laboratories, and this appearance was due to the smaller number of colonies scored. Thus, these results demonstrate that the IWGT protocol for the TGR assays is valid, and show that consistent results are obtained among diŠerent laboratories.
The transgenic rodent (TGR) assay has been widely used to study in vivo gene mutations by chemicals or radiation; however, an optimal protocol has not yet been established to assess unknown genotoxic potential. The International Workshop on Genotoxicity Testing (IWGT) strongly recommends a repeated-dose regimen for the TGR assay protocol for regulatory safety assessment as follows: a treatment period of 28 days and a sampling time of 3 days following theˆnal treatment. In this study, TGR assays using F344 gpt delta transgenic rats were conducted at three laboratories to evaluate the validity of the IWGT protocol, as part of a collaborative study of the transgenic rat mutation assay. Male F344 gpt delta transgenic rats were orally treated with 2,4-diaminotoluene (2,4-DAT; hepatic carcinogen in rodents; 10 and 30 mg/kg/day) or 2,6-diaminotoluene (2,6-DAT; non-carcinogen in rodents; 60 mg/ kg/day) once daily for 28 days. Rats were euthanized 3 days after the last dosing, and then mutant frequencies (MFs) of the gpt gene in the livers were studied. As a result, a signiˆcant increase in the MF was observed at 30 mg/kg in the 2,4-DAT-treated group, but not in the 2, 6 Introduction Transgenic rodent (TGR) assays have been widely used to study in vivo gene mutations by chemicals or radiation; however, an optimal protocol has not yet been established to assess unknown genotoxic potential. The International Workshop on Genotoxicity Testing (IWGT) strongly recommends a repeated-dose regimen for the TGR assay protocol for regulatory safety assessment as follows: a treatment period of 28 days and a sampling time of 3 days following theˆnal treatment (i.e., IWGT protocol) (1, 2) . The monograph criteria for TGR mutagenicity assays published by the World Health Organization (WHO) are consistent with the IWGT protocol (3); however, little TGR assay data have been obtained using the IWGT protocol.
In this study, we conducted the TGR assays at three diŠerent laboratories using F344 gpt delta transgenic rats to evaluate the validity of the IWGT protocol, as a part of a collaborative study of the transgenic rat mutation assay. We used F344 gpt delta transgenic rats because of its useful features (see below).
For gpt delta transgenic rodents, transgenic mice werê rst developed as a new model in 1996 (4). Subsequent- ly, Sprague-Dawley (SD) gpt delta transgenic rats (5) and F344 gpt delta transgenic rats (6) were developed in 2003 and 2010, respectively. The TGR assay using gpt delta transgenic rodents has two distinct selections for detecting diŠerent types of mutations: 6-thioguanine (6-TG) selection (i.e., gpt assay) for point mutations such as base substitutions and frameshifts, and Spi -selection for deletion mutations (4). F344 gpt delta transgenic rats also have the advantage that its background strain (i.e., F344 strain) is frequently used for the 2-year cancer bioassay (6) . In this study, we used 2,4-diaminotoluene (2,4-DAT) and 2,6-diaminotoluene (2,6-DAT). 2,4-DAT is carcinogenic in rodents, inducing liver, mammary gland and subcutaneous tumors in rats, and liver tumors and lymphomas in female mice (7), while 2,6-DAT does not induce tumors in rats or mice (8) .
Diaminotoluenes have been extensively studied in genotoxicity assays. For in vitro genotoxicity studies, both 2,4-DAT and 2,6-DAT are mutagenic in the Ames test (9-12). 2,4-DAT induces DNA damage, DNA repair and micronucleus formation in the metabolically competent HepG2 cell line (13) . Using rat and human hepatocytes in vitro, both 2,4-DAT and 2,6-DAT induce DNA repair (14, 15) , but 2,4-DAT is inactive by an alkaline elution assay for DNA strand breaks (16) .
For in vivo genotoxicity studies, 2,4-DAT induces unscheduled DNA synthesis (UDS) in the rat liver, while 2,6-DAT does not (17) . 2,4-DAT induces DNA damage (comets) in the mouse liver, while 2,6-DAT does not (18) . 2,4-DAT induces LacI, LacZ and gpt mutations in the liver of Big Blue TM mice (19, 20) , Muta TM Mouse transgenic mice (21) and F344 gpt delta transgenic rats (6), respectively, while 2,6-DAT does not (6, 20, 21) . Both 2,4-DAT and 2,6-DAT weakly induce micronuclei in rat bone marrow (22) , while neither 2,4-DAT nor 2,6-DAT in peripheral blood of F344 gpt delta transgenic rat (6) .
Thus, in vivo genotoxicity studies in the liver are able to discriminate between the carcinogen 2,4-DAT and the non-carcinogen 2,6-DAT. In particular, the results of TGR assays using the liver are correlated with those of the bioassays for carcinogenicity of 2,4-DAT and 2,6-DAT; however, the MF is not increased when the treatment period (19) and the sampling time (20) are not appropriate. Thus, the treatment period and the sampling time are important factors in the TGR assay protocol. In this collaborative study, we conducted TGR assays by the IWGT protocol with 2,4-DAT and 2,6-DAT to evaluate the validity of the IWGT protocol.
Materials and Methods
Participating laboratories: Laboratories that participated in this study are shown in Table 1 .
Animal housing, treatment of animals and tissue collection for the ENU-treated group were conducted at Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd. (Kanagawa, Japan), and those for all other treated groups were conducted at Lab D3. In this collaborative study, the gpt mutation assays were performed at three laboratories (i.e., Labs D1-D3) after preliminary technical training. Test chemicals: 2,4-Diaminotoluene (2,4-DAT; CAS no. 95-80-7, 99.9z pure), 2,6-diaminotoluene (2,6-DAT; CAS no. 823-40-5, 99.5z pure) were purchased from Sigma-Aldrich Chemical Co. (St Louis, MO, USA). N-Ethyl-N-nitrosourea (ENU; CAS no. 759-73-9) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Distilled water and physiological saline were purchased from Hikari Pharmaceutical Co., Ltd. (Tokyo, Japan) and Otsuka Pharmaceutical Factory, Inc. (Tokushima, Japan), respectively. 2,4-DAT was dissolved in distilled water (2 and 6 mg/mL). 2,6-DAT was suspended in distilled water (12 mg/mL). ENU was dissolved in physiological saline (5 mg/mL). All test chemical solutions and suspensions were stored in a refrigerator under shaded conditions until use, and used for treatment withinˆve days after preparation.
Animals and treatment: Male 6-week-old F344/ NSlc-Tg (gpt delta) rats (i.e., F344 gpt delta transgenic rats) were obtained from Japan SLC, Inc. (Shizuoka, Japan). The animals were observed daily for their general conditions for at least seven days (i.e., quarantine period). The 7-week-old healthy rats during the quarantine period were randomly assigned to the control and treated groups, and then used for the study. The animals were individually housed in TPX cages (CLEA Japan, Inc., Tokyo, Japan) on paper-based bedding, Paper-clean (Japan SLC, Inc.), with pellet chow and tap water ad libitum in an air-conditioned room (12 h light/ 12 h dark cycle; 21-259 C; 40-75z humidity).
The animals (6 rats/group) were treated by oral gavage with distilled water (i.e., vehicle control), 2,4-DAT (10 and 30 mg/kg/day) or 2,6-DAT (60 mg/kg/day) at a dosing volume of 5 mL/kg once a day for 28 consecutive days (7, 8) . For the positive control group,ˆve rats were treated intraperitoneally with ENU (50 mg/kg/day; 10 mL/kg) once a day forˆve consecutive days. Changes in the general condition and body weight of treated animals were monitored regularly until the dissection day. The animal experiments were conducted in accordance with the guideline in each laboratory.
Tissue collection and delivery: All treated animals except for the ENU-treated group were euthanized 3 days after the last treatment by exsanguination under deep anesthesia with sodium pentobarbital. The livers (i.e., target organ for carcinogenesis) and kidneys (i.e., non-target organ) were collected and weighed. The liver was divided into four aliquots, quickly frozen in liquid nitrogen, and stored below -709 C until delivery to the participants. For the ENU-treated group,ˆve treated animals were euthanized 26 days after the last treatment. The liver was isolated and cut into slices, quickly frozen in liquid nitrogen, and stored below -709 C until delivery to the participants. Liver samples from rats in the ENU-treated group were delivered by the Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd. (Kanagawa, Japan), and those in all other treated groups were delivered by Lab D3 to the participating laboratories. The liver samples were stored below -709 C until used for genomic DNA isolation in each laboratory.
For all treated animals except for the ENU-treated group, histopathological and biochemical examinations were also performed to examine the general toxicities by 2,4-DAT and 2,6-DAT. For histopathological examination, a portion of each tissue (i.e., liver and kidney) from each animal wasˆxed in 10z buŠered formalin solution, and routinely processed into para‹n blocks. Hematoxylin and eosin-stained tissue preparations cut from the blocks were examined by light microscopy. For biochemical examination, the blood was collected from the abdominal caval vein of rats using heparinized plastic syringes, and routinely processed into plasma samples, which were analyzed with an automated clinical biochemistry analyzer (JCA-BM6010; Japan Electron Optics Laboratory Ltd., Tokyo).
Extraction of genomic DNA: High molecular weight total genomic DNA was extracted from the liver by the standard phenol/chloroform method (23) at Lab D1, and using the RecoverEase TM DNA Isolation kit (Agilent Technologies, Santa Clara, CA) at Labs D2 and D3. The genomic DNA was stored at 49 C until used for in vitro packaging.
In vitro packaging: The l phage vectors (i.e., l EG10) carrying gpt genes were recovered from genomic DNA by in vitro packaging reactions, which were carried out using Transpack } Lambda Packaging Extract (Agilent Technologies) according to the manufacturer's instructions. The phage solutions were used for gpt mutation assay immediately after preparation or stored at 49 C and then used within four days after preparation.
gpt Mutation assay: Five animals (at Labs D1 and D3) or six animals (at Lab D2) per group were analyzed by the gpt mutation assay, which was performed according to the previously published methods (4, 24 
The bacterial strains (i.e., Escherichia coli C and YG6020) were delivered from the Division of Genetics and Mutagenesis, National Institute of Health Sciences (Tokyo, Japan) to each participating laboratory. These strains were stored below -709 C until use.
Statistical analysis: The MFs were statistically analyzed using total MFs which were calculated after summation of total colonies and mutant colonies, respectively, from three laboratories, and individual MFs which were calculated by the values of each laboratory. The total MFs were ofˆve animals per group (i.e., data of sixth animal in each group assayed only at Lab D2 was omitted). Variance was analyzed by Bartlett's test ( pº0.05) between the MF in each 2,4-DAT-and 2,6-DAT-treated group and the vehicle control group. Subsequently, multiple comparisons of the treated groups with the vehicle control group were performed using either Dunnett's test (parametric, one-tailed) (25,26) or Steel's test (one-tailed) (27) . For MF in the ENU-treated group, variance was analyzed by the F test ( pº0.05). Subsequently, pairwise comparison of the ENU-treated group with the vehicle control group was performed using either Student's t-test (one-tailed) or Welch's t-test (one-tailed). For body weight, hematology, blood chemistry and organ weights, variance was analyzed by the F test (pº0.05) between the values in each 2,4-DAT-or 2,6-DAT-treated group and the vehicle control group. Subsequently, pairwise comparison of each treated group with the vehicle control group was performed using either Student's t-test (two-tailed) or Welch's t-test (two-tailed).
Results
gpt Mutant frequency in liver: Summary data of total MF from three laboratories are shown in Table 2 , and depicted in Figs. 1 and 2 . The numbers of colonies scored per animal were not less than 900,000 (Table 2) . Total MF in the vehicle control group was similar between animals, 1.14-2.98×10 -6 (mean value: 1.80× 10 -6 ), which are slightly lower than in the previous report (i.e., 4.4×10 -6 ) (28). All total MFs from each animal in 10 and 30 and 10.66-21.67×10 -6 , respectively) were higher than in the vehicle control group (approximately 3.3 and 8.7 times, respectively), with signiˆcance (both pº0.05; Steel's test) and increased in a dose-related manner (Table 2 and Fig. 1 ). In contrast, almost all total MFs from each animal in the 2,6-DAT-treated group (i.e., 1.77-5.85×10 -6 ; mean value: 3.30×10 -6 ) were similar to the vehicle control group, and were not signiˆcantly increased (Table 2 and Fig. 1 ). The total MF from one animal (i.e., 5.85×10 -6 ) in the 2,6-DAT-treated group was similar to that in the 10 mg/kg/day 2,4-DAT-treated group (Table 2 ).
All total MFs from each animal in ENU-treated group (53.26-91.52×10 -6 ; mean value: 79.43×10 -6 ) were apparently higher than the vehicle control group (approximately 44.1 times), and were signiˆcantly increased ( pº0.001; Welch's t-test) ( Table 2 and Fig. 3) .
The individual mean MFs are shown in Table 3 and Figs. 2 and 3. Detailed data from each laboratory are presented in online supplemental Appendices 1-3 at http://www.j-ems.org/ journal/. The individual mean MFs in the vehicle control group (i.e., 1.88, 3.06 and 1.93×10 -6 , respectively) were similar among the three 
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Collaborative Study Using gpt delta Transgenic Rat laboratories (Table 3 ). In the 10 and 30 mg/kg/day 2,4-DAT-treated groups, the MFs from Labs D1 and D3 increased in a dose-related manner, and a signiˆcant diŠerence was observed compared with the vehicle control (Table 3 and Fig. 2) . Meanwhile, there was no signiˆcant increase in the MF from Lab D2 in any 2,4-DAT-treated group; although, the mean MF in 30 mg/kg/day 2,4-DAT-treated group (i.e., 7.34×10 -6 ) was approximately 2.4 times higher than that in the vehicle control (i.e., 3.06×10 -6 ) ( Table  3 and Fig. 2) . Thus, increase in the MF by 2,4-DAT treatment was observed in all laboratories, which agreed with the results obtained for the total MF from the three laboratories.
In the 2,6-DAT-treated group, no signiˆcant increase was observed in the MF from any laboratory, which agreed with the results obtained for total MF (Table 3 and Fig. 2 ).
In the ENU-treated group (i.e., positive control group), all individual mean MFs apparently increased (mean values: 63.02, 74.82 and 154.44×10 -6 , respectively) signiˆcantly when compared with the vehicle control (Table 3 and Fig. 3 ).
From these results, 2,4-DAT and ENU increased gpt MF in the liver of male F344 gpt delta transgenic rats in this study, but 2,6-DAT did not.
General toxicity evaluation: The summary of general toxicity data is shown in Table 4 . Changes in the general condition of animals were observed only in the 2,6-DAT-treated group. There were no deaths in any treated group. Body weights of animals were signiˆcant-ly decreased in 30 mg/kg/day 2,4-DAT-and 2,6-DATtreated groups. Signiˆcant changes in the hematological and blood biochemicalˆndings were observed in both 2,4-DAT-and 2,6-DAT-treated groups. Weights of the liver and kidneys were signiˆcantly decreased only in the 2,6-DAT-treated group. Histologicalˆndings of the kidneys in both 2,4-DAT-and 2,6-DAT-treated groups were similar to the vehicle control group; however, for the liver, proliferation of bile duct and single cell necrosis of hepatocytes, which were very slight or slight, were observed in all animals in the 30 mg/kg/day 2,4-DATtreated group. These histologicalˆndings are presented in online supplemental Appendix 4 at http://www.jems.org/journal/. Very slight single cell necrosis of hepatocytes was observed in one animal in the vehicle control group. Very slight hypertrophy of hepatocytes was observed in three animals each in the 30 mg/kg/day 2,4-DAT-treated and 2,6-DAT-treated groups. No histological changes of the liver were observed in the 10 mg/kg/day 2,4-DAT-treated group.
Discussion
In this collaborative study of the transgenic rat mutation assay, three participating laboratories conducted the gpt mutation assay using the liver of F344 gpt delta transgenic rats treated with 2,4-DAT or 2,6-DAT to evaluate the validity of the IWGT protocol (i.e., treatment period of 28 days and sampling time of 3 days following theˆnal treatment).
In this collaborative study, the individual mean MFs in the vehicle control group (i.e., 1.88×10 -6 at Lab D1; 3.06×10 -6 at Lab D2; 1.93×10 -6 at Lab D3) were similar between laboratories (Table 3 and Fig. 2) . Although the data of MF in the liver of F344 gpt delta transgenic rats are limited, they were previously reported as follows: 6.02±2.38×10 -6 (6) and 4.4×10 -6 (28) in the untreated group. Thus, the individual mean MFs in the vehicle control group of this study were likely values; Table 4 . General toxicity of 2,4-DAT and 2,6-DAT in male F344 gpt delta transgenic rats
Group
Distilled water: vehicle control 2,4-DAT 2,4-DAT 2,6-DAT (mg/kg/day) (0) (10) (30)
Number of animals 6 6 6 6 
General conditions
Decrease in locomotor activity 0 0 0 6 Eyelid closure 0 0 0 6 Salivation 0 0 0 2 Body weights- & & Hematologicalˆndings RBC % % - MCV - $ - MCH $ $ - Neutrophil - - $ Platelet $ $ & Blood biochemicalˆndings TP - % % Total cholesterol $ $ % Triglyceride % - & Phospholipid $ $ & Ca - - % Total bilirubin - # - Inorganic phosphorus - # - Organ weight (absolute) Liver - - & Kidneys - - & Organ weight (relative) Liver $ $ - Kidneys - $ $
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however, they were slightly lower than reported previously.
In this collaborative study, liver samples from ENUtreated animals were used as a positive control. ENU increased the total MF (79.43×10 -6 ) which was approximately 44.1 times higher than in the vehicle control group (Table 2 and Fig. 3 ). Clear increases in MF (i.e., approximately 33.5 times at Lab D1; approximately 24.5 times at Lab D2; approximately 80.0 times at Lab D3) were also observed in each mean MF from three laboratories (Table 3 and Fig. 3 ). These positive results coincide with previous reports using gpt delta transgenic mice (29) . Thus, the results of both (i.e., vehicle and positive) control groups indicate that the total data from the three laboratories in this study are reliable.
In previous reports, 2,4-DAT, a liver carcinogen in rats and mice, gave negative and positive results in the TGR mutagenicity assays as follows: increase in LacI (21); approximately 2.2-7.1 times increase in gpt MF and 1.9-3.6 times increase in Spi -MF of liver samples from male F344 gpt delta transgenic rats with a treatment period of 13 weeks (125, 250 and 500 ppm in the diet) (6) . These data indicate that adequate dosing (i.e., treatment period) and sampling (i.e., sampling time and sampling organ) regimens may be necessary to observe the in vivo gene mutations induced by 2,4-DAT treatment.
In this collaborative study, total MFs from three laboratories in 10 and 30 mg/kg/day 2,4-DAT-treated groups were 6.00×10 -6 and 15.74×10 -6 , approximately 3.3 and 8.7 times higher than in the vehicle control group, respectively (Table 2 and Fig. 1) . Thus, clear increases in total MF were observed by 2,4-DAT treatment, dose-dependently.
Similar increases in MF at two doses were also observed in the individual mean MF from two laboratories, Lab D1 and Lab D3, that is, signiˆcant increases in mean MF in 10 and 30 mg/kg/day 2,4-DAT-treated groups (i.e., 3.7 and 4.6 times at Lab D1; 5.2 and 18.7 times at Lab D3) were observed (Table 3 and Fig. 2) . At Lab D2, there was no signiˆcant increase in MF in any 2,4-DAT-treated group; however, the mean MF in the 30 mg/kg/day 2,4-DAT-treated group was 2.4 times higher than in the vehicle control. We speculate that the results of the 2,4-DAT treated group at Lab D2 may have been caused as follows: zero MF, which was frequently observed in the vehicle control and 10 mg/kg/day 2,4-DAT-treated group, and high MF (i.e., 10.58×10 -6 ) from one animal in the vehicle control group (Appendix 2). Especially, this high MF was calculated by a small number of colonies scored, and it was considered that this MF in‰uenced the variability of MF in the vehicle control group. In fact, this single MF in the vehicle control group was determined as an outlier by a box-and-whisker plot (30) . Thus, this outlier value was excluded and then the statistical re-analysis was conducted for the results of Lab D2. As a result, the statistical re-analysis showed that a signiˆcant increase (pº0.01) in MF in 30 mg/kg/day 2,4-DAT-treated group (data not shown).
On the other hand, 2,6-DAT, a non-carcinogen in rodents, did not signiˆcantly increase either total MF from the three laboratories or individual MFs from each laboratory in this study (Table 3) . Thus, the results obtained in this study agreed with the previous reports as follows: 2,6-DAT give only negative results in TGR mutagenicity assays using Big Blue TM , Muta TM Mouse transgenic mice (20, 21) and F344 gpt delta transgenic rats (6) . Approximately 1.8 times increase was observed in the total MF in 2,6-DAT-treated group in this study; however, we speculate that this slight increase in total MF in the 2,6-DAT-treated group may have been caused by the MF (i.e., 12.82×10 -6 ) from one animal at Lab D3, which had a low colony count (i.e., 156,000) (Appendix 3).
In this study, we identiˆed the signiˆcant decrease of body weight in the 30 mg/kg/day 2,4-DAT-and 60 mg/kg/day 2,6-DAT-treated groups. The decrease in the 2,6-DAT-treated group was most notable, followed by 30 mg/kg/day and 10 mg/kg/day 2,4-DAT-treated groups. In these groups, the histological changes in the liver (i.e., hypertrophy and single cell necrosis of hepatocyte etc.) were also observed in many rats, and these types and the number of corresponding rats were diŠerent from that observed in the vehicle control group (Table 4 and Appendix 4). In the 60 mg/kg/day 2,6-DAT-treated group, the signiˆcant decrease of liver weight was also observed. Thus, these general toxicitŷ ndings indicate that the livers of F344 gpt delta rats were exposed to the test chemicals (i.e., 2,4-DAT and 2,6-DAT), and the doses used in this study were su‹cient for evaluation of the TGR mutagenicity assays.
In the present study, 2,6-DAT was negative in genotoxicity. This negative result was consistent with the results of carcinogenicity study (8) and the other in vivo genotoxicity assays (6, (17) (18) (19) (20) (21) . However, weakly positive result of 2,6-DAT in the rat bone marrow micronucleus study is present (22) . This point remains to be clariˆed.
In the present study, the standard deviations were larger than the mean value in the individual mean MF of all experimental groups except for the higher dose of 2,4-DAT and the positive control groups, obtained at Lab 2 (Appendix 2). In these experimental groups, zero 6TG r mutant was also observed frequently. We suggest that TGR mutagenicity assays are repeatedly conducted on diŠerent experimental dates for all animals to conrm the reproducibility of the MF obtained from each assay and to accumulate a larger total population. Actually, total population analyzed at Lab D2 was the smallest among three laboratories. In the previous report, for phage-based assays, a minimum of 125,000 to 300,000 colony (or plaque) per animal is required if spontaneous mutant frequency is in the order of ¿3× 10 -5 mutants andˆve to 10 animals per group are analyzed (31) .
In conclusion, all three laboratories could distinguish the diŠerences in the in vivo mutagenic potential between a hepatic carcinogen (i.e., 2,4-DAT) and a noncarcinogen (i.e., 2,6-DAT) by the F344 gpt delta transgenic rat mutation assay using the IWGT protocol. Consequently, the validity of the IWGT protocol for the TGR assays was conˆrmed in this collaborative study. Because there are still limited data available using the IWGT protocol, further studies using other compounds are needed to validate the TGR assay conducted by the IWGT protocol.
